Terns Pharmaceuticals (NASDAQ:TERN) Announces Earnings Results, Beats Expectations By $0.04 EPS

Terns Pharmaceuticals (NASDAQ:TERN) released its quarterly earnings results on Monday. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.04, Zacks reports.

Terns Pharmaceuticals Stock Down 2.6 %

Shares of Terns Pharmaceuticals stock traded down $0.19 during trading on Tuesday, reaching $7.12. The company’s stock had a trading volume of 1,380,944 shares, compared to its average volume of 1,003,095. Terns Pharmaceuticals has a 52-week low of $3.26 and a 52-week high of $10.03. The firm’s 50-day moving average is $7.60 and its two-hundred day moving average is $6.65. The company has a market cap of $460.52 million, a price-to-earnings ratio of -6.29 and a beta of -0.37.

Insider Buying and Selling

In other Terns Pharmaceuticals news, Director Jill M. Quigley sold 6,143 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $7.68, for a total transaction of $47,178.24. Following the completion of the sale, the director now directly owns 23,857 shares in the company, valued at $183,221.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Carl L. Gordon sold 50,976 shares of Terns Pharmaceuticals stock in a transaction on Monday, July 15th. The shares were sold at an average price of $10.00, for a total value of $509,760.00. Following the transaction, the director now directly owns 756,258 shares of the company’s stock, valued at $7,562,580. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jill M. Quigley sold 6,143 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $7.68, for a total transaction of $47,178.24. Following the sale, the director now owns 23,857 shares of the company’s stock, valued at $183,221.76. The disclosure for this sale can be found here. 15.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TERN has been the subject of several analyst reports. JMP Securities restated a “market outperform” rating and set a $15.00 price target on shares of Terns Pharmaceuticals in a report on Tuesday, April 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.50 target price on shares of Terns Pharmaceuticals in a report on Tuesday, May 14th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $19.00 price target on shares of Terns Pharmaceuticals in a report on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.50.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.